The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000540.3(RYR1):c.2122G>A (p.Asp708Asn)

CA024331

159840 (ClinVar)

Gene: RYR1
Condition: malignant hyperthermia, susceptibility to, 1
Inheritance Mode: Autosomal dominant inheritance
UUID: 0ec2283f-baa3-4edb-9865-94902ad87666
Approved on: 2023-04-07
Published on: 2023-04-07

HGVS expressions

NM_000540.3:c.2122G>A
NM_000540.3(RYR1):c.2122G>A (p.Asp708Asn)
NC_000019.10:g.38458247G>A
CM000681.2:g.38458247G>A
NC_000019.9:g.38948887G>A
CM000681.1:g.38948887G>A
NC_000019.8:g.43640727G>A
NG_008866.1:g.29548G>A
ENST00000599547.6:n.2122G>A
ENST00000359596.8:c.2122G>A
ENST00000355481.8:c.2122G>A
ENST00000359596.7:n.2122G>A
ENST00000360985.7:c.2122G>A
NM_000540.2:c.2122G>A
NM_001042723.1:c.2122G>A
NM_001042723.2:c.2122G>A

Uncertain Significance

The Expert Panel has overridden the computationally generated classification - "[unknown]"
Not Met criteria codes 7
BP4 BA1 PS3 PS4 PP3 PM1 BS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Malignant Hyperthermia Susceptibility VCEP
This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of Aspartic acid with Asparagine at codon 708 of the RYR1 protein, p.(Asp708Asn). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.0007, a frequency consistent with pathogenicity for MHS. This variant has been reported in individuals with congenital myopathies inherited in an autosomal recessive pattern. No functional studies were identified for this variant. This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. A REVEL score of 0.726 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as a Variant of Unknown Significance. No criteria were implemented.
Not Met criteria codes
BP4
A REVEL score of 0.726 supports neither a pathogenic nor a benign status for this variant.
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No functional studies were identified for this variant.
PS4
This variant has been reported in individuals with congenital myopathies inherited in an autosomal recessive pattern.
PP3
A REVEL score of 0.726 supports neither a pathogenic nor a benign status for this variant.
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
High MAF in AJ population (0.00388), not considered for BS1. Likely too high for a pathogenic variant.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.